Isolation and Quantitation of a Minor Determinant of Hen Egg White Lysozyme Bound to I-A<sup>k</sup> by Using Peptide-Specific Immunoaffinity

Raffi Gugasyan, Ilan Vidavsky, Christopher A. Nelson, Michael L. Gross and Emil R. Unanue

*J Immunol* 1998; 161:6074-6083; ;
http://www.jimmunol.org/content/161/11/6074

---

**References**  This article cites 41 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/161/11/6074.full#ref-list-1

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Isolation and Quantitation of a Minor Determinant of Hen Egg White Lysozyme Bound to I-A<sup>k</sup> by Using Peptide-Specific Immunoaffinity

Raffi Gugasyan,* Ilan Vidavsky,† Christopher A. Nelson,* Michael L. Gross,† and Emil R. Unanue<sup>1*</sup>

We report here the identification and quantitation of a minor epitope from hen egg white lysozyme (HEL) isolated from the class II MHC molecule I-A<sup>k</sup> of APCs. We isolated and concentrated the peptides from the I-A<sup>k</sup> extracts by a peptide-specific mAba, followed by their examination by electrospray mass spectrometry. This initial step improved the isolation, recovery, and quantitation and allowed us to identify 13 different minor peptides using the Ab specific for the HEL tryptic fragment 34–45. The HEL peptides varied on both the amino and carboxy termini. The shortest peptide was a 13-mer (residues 33–45), and the longest peptide was a 19-mer (residues 31–49). The two most abundant were 31–47 (1.3 pmol) and 31–46 (1 pmol), while the least abundant were 31–45 (40 fmol) and 32–45 (4 fmol). Only 0.3% of the total class II molecules were occupied by this family of HEL peptides. The amount of the 31–47 peptide, the predominant member of this series, was 22 times lower than that of 48–62, the major epitope of HEL. The 31–47 peptide bound about 20-fold weaker to I-A<sup>k</sup> compared with the dominant 48–62 peptide. Thus, the lower abundance of the minor epitope correlated with its weaker binding strength.

Recently, the combined strategy of immunoaffinity chromatography and mass spectrometry analysis was employed for the characterization of peptide fragments from proteins (24–26) and for the isolation of limiting amounts of protein from complex biologic material (27, 28). We have now adapted the principle of immunoaffinity capture and developed it as a strategy to isolate low abundance class II-associated peptides. Using a monoclonal anti-peptide Ab, we recovered picomole-to-femtomole levels of HEL peptides, which were previously identified in the tryptic fragment 34–45 (29).

**Materials and Methods**

**Cell lines**

We used the murine B cell lymphoma line M12.C3.F6 transfected with a membrane form of HEL (M12-A^k^ mHEL) (11). The HEL fusion protein was engineered with site-directed mutagenesis by using a procedure previously described by Brooks et al. (30). Our control cell line, M12.C3.F6, expressing class II I-A^k^ (M12-A^k^) (31), and M12-A^k^ mHEL were cultured in DMEM supplemented with 5% FCS. The M12-A^k^ mHEL process and present HEL peptides equally to M12-A^k^ given exogenous HEL (11).

**Production of mAbs**

mAbs to HEL peptides were produced by standard hybridoma procedures. Briefly, the synthetic HEL peptide 34–45 was coupled to the carrier protein keyhole limpet hemocyanin using bromoacetyl succinimide (Sigma, St. Louis, MO). CAF.1/J mice (The Jackson Laboratories, Bar Harbor, ME) were first injected i.p. with peptide-hemocyanin (CFA) (Sigma), followed by three i.p. injections in incomplete CFA (Sigma) at 4–6-wk intervals. Finally, 3 days before B cell fusion, the mice were boosted i.v. with 25 μg of peptide-hemocyanin in sterile PBS. Splenocytes were fused with the myeloma fusion partner P3X63.Ag8 at a ratio of 5:1. Cell fusion was induced with polyethylene glycol 1500 (Boehringer Mannheim, Indianapolis, IN) by using the standard fusion protocol. The hybridoma supernatants were screened by an ELISA assay in which 96-well Maxisorp plates (NUNC, Roskilde, Denmark) were coated with 5 μg/ml of denatured HEL (Sigma). The positive wells were then cloned. Six Abs were found to be specific for the HEL peptide 34–45, of which VAL-3 (isotype IgG1) was used. The epitope of this Ab is on the amino terminus spanning from residues 34–38 (FESNF). VAL-3 hybridoma cells were injected into pristane (Sigma)-treated SCID mice, and the IgG1 Ab was purified from ascites using protein A-Sepharose (Sigma).

**Synthesis of synthetic peptides**

Peptides were synthesized by F-moc chemistry (model 432A; Applied Biosystems, Foster City, CA) and purified by reverse-phase HPLC (600E; Waters, Milford, MA). The sequences of all peptides were subsequently confirmed by mass spectrometry. For binding studies, peptides were radioiodinated (125I) on Tyr residues using the chloramine-T method (32). Each peptide was iodinated to a specific activity of 0.5 mCi/1.5 nmol of peptide.

**Isolation of I-A^k^-associated HEL peptides**

I-A^k^ molecules were isolated from M12-A^k^ mHEL B lymphoma cells (10) and grown to a cell density of 2 × 10^7 cells/ml to yield a total of 10^10 cells. These cells were lysed in the presence of MEGA 8/MEGA 9 detergent (Sigma) and enzyme inhibitors (PMSF, iodoacetamide, and leupeptin) as described (10). The I-A^k^ molecules were isolated by immunoaffinity chromatography using the anti-I-A^k^ Ab 40F (33). The peptides were subsequently released by acid treatment. In the experiment shown in Fig. 1, each peptide was separated by conventional reverse-phase HPLC (600E; Waters) respectively. Each 250-μl fraction was tested in a T cell bioassay using either the T cell hybridoma A6A2. Class II molecules were purified by immunoaffinity chromatography from 10^10 M12-A^k^ mHEL cells. The peptides were released by acid treatment and subsequently fractionated by reverse-phase HPLC. A. An amount of each 250-μl fraction was screened in a T cell bioassay, and the production of IL-2 was measured by CTLL proliferation. At 48 min, five fractions contained HEL peptides reactive to the T cell hybridoma A6A2, while at 72 and 78 min, five fractions containing HEL peptides with a core region of 52–61 stimulated the 3A9 T cell hybridoma. B. Fractions eliciting an A6A2 T cell response (shown in A) were analyzed by MALDI-TOF mass spectrometry. Compared with the theoretical masses of 1812.86 and 1913.91, weak signals were observed at masses of 1814.58 and 1916.33, which corresponded to the HEL peptides 31–46 and 31–47, respectively. The data are representative of two experiments.

For the isolation of peptides by peptide-specific immunoaffinity, we used lysates from 10^9 M12-A^k^ mHEL cells. The procedure consisted of five consecutive steps: 1) capture of the I-A^k^ molecules using 40F Ab (40F binds to all I-A^k^ molecules), 2) release of peptides bound to I-A^k^, 3) capture of the peptide by the Ab to 34–45, 4) release of the peptide, and 5) analysis of the peptide by mass spectrometry. Specifically, the cell lysate was incubated for 2 h at 4°C with the Ab 40F coupled to cyanogen bromide-activated Sepharose beads (Sigma). Next, the material was loaded into a disposable 14-cm Polyprepn chromatography column (Bio-Rad, Hercules, CA) and washed with at least 20 column volumes of wash buffer (20 mM MEGA 8/MEGA 9 in PBS). The I-A^k^ peptide complexes were subsequently eluted with 0.1% TFA, causing the simultaneous dissociation of this complex. The free peptide mixture was neutralized with 1 M Tris, pH 7.4, and then passed through a Centricron-10 concentrator (Amicon, Beverly, MA) to exclude the high molecular mass material. In a second chromatography step, this mixture was incubated with VAL-3 coupled to cyanogen bromide-activated Sepharose beads (Sigma). Next, the material was loaded into a disposable 14-cm Polyprepn chromatography column (Bio-Rad, Hercules, CA) and washed with at least 20 column volumes of wash buffer (20 mM MEGA 8/MEGA 9 in PBS). The I-A^k^ peptide complexes were subsequently eluted with 0.1% TFA, causing the simultaneous dissociation of this complex. The free peptide mixture was neutralized with 1 M Tris, pH 7.4, and then passed through a Centricron-10 concentrator (Amicon, Beverly, MA) to exclude the high molecular mass material. In a second chromatography step, this mixture was incubated with VAL-3 coupled to cyanogen bromide-activated Sepharose beads to concentrate the 34–45 reactive peptides. (Ten milligrams of VAL-3 was incubated with 1 g of cyanogen bromide-activated Sepharose 4B, resulting in about 95% coupling; 500 μl of a 50% v/v of the VAL-3-conjugated beads was incubated with 5 ml of peptide extract.) After an overnight rotation at 4°C, the slurry was loaded into a 9-cm disposable Polyprepn chromatography column. The Sepharose was washed with 20 column volumes of 0.01 M Tris, pH 7.4, and 5 column volumes of Milli-Q water for the removal of excess salt. The bound peptides were eluted with 0.1% TFA into siliconized microfuge tubes; six fractions were collected at 250 μl per fraction. Each fraction
was dried down; reconstituted in a total volume of 80 μl of a 2% acetonitrile, 0.6% acetic acid solution; and then pooled. The sample was subsequently subjected to tandem mass spectrometry.

Analysis by mass spectrometry

For MALDI-TOF mass spectrometry analysis, 0.5 μl of the sample (from the standard method) was mixed with 0.5 μl of the MALDI matrix solution 4-hydroxyacetoncinamic acid (Hewlett-Packard, Chicago, IL) on the matrix plate. MALDI-TOF analysis was performed in the linear mode on a PerSeptive Voyager-RP Reflectron instrument (PerSeptive Diagnostics, Framingham, MA) using the Voyager and GRAMS/386 software. The accelerating voltage was 25–30 kV, and the ions were desorbed by an N2 laser at 1 = 337 nm with a 3–ns pulse width.

Samples from many of the experiments were subjected to capillary reverse-phase HPLC mass spectrometric analysis. Using the Rheodyne 7125 injector, we injected 15 μl of the prepared sample into the reverse-phase HPLC, which consisted of a Zorbax C18, 0.3-μm × 25-cm column (MicroTech, Sunnyvale, CA). Conditions of the gradient were as follows: solvent A (6% acetic acid in water) was kept constant at 10%; solvent B (acetonitrile) was kept constant at 2% for the first 5 min, increased from 2 to 15% in the next 5 min, and then increased from 15 to 90% at a rate of 0.9%/min; and solvent C (water) maintained the mixture at 100% while the eluent flow rate was maintained at 4.5 μl/min. The HPLC pump was a Waters 600MS equipped with pulse damping (silk board). The flow from the pump was split by using the LC packing accurate splitter with a 0.3-μm-wide column (LC Packing, San Francisco, CA). The total column effluent was then directed at the mass spectrometer.

Peptides were identified by mass and sequenced on a Finnigan liquid chromatography quadrupole ion-trap mass spectrometer (Finnegan, San Jose, CA) (i.e., in the MS and MS/MS modes, respectively). For MS mode, the scan range was at a mass-to-charge ratio (m/z) of 600-1300 in the profile mode, in which every three microscans were averaged to one scan. Acquisition was started 10–15 min after the commencement of the LCQ run. For MS/MS mode, the scan range was m/z 250-1850, again in profile mode, in which every three microscans were averaged to one scan. The parent ion was isolated with a mass window that was 2 m/z wide, and the collision energy was 25% of the maximum energy. Sequence analysis was performed by comparing the experimental ion mass with the calculated ion mass or by an automated protein database sequencing program (SEQUEST, John Yates, University of Washington, Seattle, WA) on an ICIS workstation (Finnegan).

Peptide-I-Ak binding strength assay

Detergent-solubilized I-Ak, purified from the T2-Ak cell line (provided by Dr. P. Cresswell, Yale University School of Medicine New Haven, CT) by affinity chromatography, was incubated with a radioactively labeled reference peptide (125I-labeled YEDYGILQINSR), a high affinity binder to I-Ak, at a final concentration of 25 pmol of 125I-reference peptide, and 25 pmol of purified I-Ak. The sequence of peptide 34–45 is Phe-Glu-Ser-Asn-Phe-Asn-Thr-Gln-Ala-Thr-Asn-Arg. The T cell response to this epitope in HEL-immunized mice was weaker, in comparison with the response of the dominant epitope 48–62. Moreover, peptide 34–45 was a weaker binder to I-Ak (29). Therefore, our initial impression was that the 34–45 epitope was subdominant or minor.

Using our standard method for peptide isolation, we found the natural form of the 34–45 peptide difficult to isolate from APC exposed to HEL. (The standard method consists of an analysis of peptides extracted from I-Ak by reverse-phase HPLC. Fractions that score positive in the T cell assay are then examined by mass spectrometry.) Earlier experiments that had been successful in isolating and characterizing the major epitope 48–62 failed to detect the 34–45 peptide (10). Two of three recent experiments revealed weak activity for the 34–45 HEL determinant. These results now are described so that a comparison can be made with the peptide immunosolation method.

Class II I-Ak molecules were purified from 1010 M12-Ak mHEL cells. By acid treatment, the complex mixture of peptides was released and then fractionated by reverse-phase HPLC. Each fraction was screened by the T-cell hybridoma 3A9 to identify the HEL peptides consisting of the core region 52–61. These peptides were identified at retention times of 72 and 78 min (Fig. 1A). In accordance with our previous observations, analysis by MALDI-TOF mass spectrometry revealed two prominent peptides, 48–62 and 48–63 (data not shown); these peptides were shown to have relative yields of 32 and 56%, respectively (10–12). In addition, each HPLC fraction was screened with the T cell hybridoma A6A2 that recognizes an epitope in the tryptic fragment 34–45. Five fractions with a retention time of 48 min showed detectable levels of IL-2, thus providing evidence for a second HEL determinant (Fig. 1A).

It is important to note that we required 36% (or 90% of the dominant HEL peptides that triggered the 3A9 T cell. Fig. 2A shows the m/z of 863 and 913, which corresponded to two members of this family, 48–62 and 47–62, respectively. In addition, the [M + 2H]2+ ions of 907.92 and 957.72 represented the minor HEL peptides 31–46 and 31–47, respectively (Fig. 1B). Clearly, the signals of the two peptides were too weak to incur any confidence in these masses.

We adjusted our approach by subjecting the T cell-positive fractions to the reverse-phase HPLC online and, this time, to the electrospray mass spectrometer, to improve the resolution of the peptide samples. Doubly charged ions [M + 2H]2+ were observed for the dominant HEL peptides that triggered the 3A9 T cell. Fig. 2A shows the m/z of 863 and 913, which corresponded to two members of this family, 48–62 and 47–62, respectively. In addition, the [M + 2H]2+ ions of 907.92 and 957.72 represented the minor HEL peptides 31–46 and 31–47, which stimulated the A6A2 T cell hybridoma. Ions to other minor HEL peptides were evident, such as the 1043.32 ion (residues 31–49) (Fig. 2A).

Thus, our initial MALDI-TOF results were confirmed. However, the abundance of these ions was still too weak among prominent contaminating peptides and thus difficult to analyze.

Results

A second HEL determinant from I-Ak molecules

Previous studies from our laboratory identified T cells directed to a tryptic fragment of HEL encompassing residues 34–45 (29). The sequence of peptide 34–45 is Phe-Glu-Ser-Asn-Phe-Asn-Thr-Gln-Ala-Thr-Asn-Arg. The T cell response to this epitope in HEL-immunized mice was weaker, in comparison with the response of the dominant epitope 48–62. Moreover, peptide 34–45 was a weaker binder to I-Ak (29). Therefore, our initial impression was that the 34–45 epitope was subdominant or minor.

Using our standard method for peptide isolation, we found the natural form of the 34–45 peptide difficult to isolate from APC exposed to HEL. (The standard method consists of an analysis of peptides extracted from I-Ak by reverse-phase HPLC. Fractions that score positive in the T cell assay are then examined by mass spectrometry.) Earlier experiments that had been successful in isolating and characterizing the major epitope 48–62 failed to detect the 34–45 peptide (10). Two of three recent experiments revealed weak activity for the 34–45 HEL determinant. These results now are described so that a comparison can be made with the peptide immunosolation method.
Using this last approach, we compared the recovery of the 31–47 peptide to the dominant HEL peptide 48–62. The abundances of these two naturally processed peptides were determined by electrospray mass spectrometry, comparing the amount recovered with known concentrations of synthetic peptide that were injected into the electrospray mass spectrometer. Fig. 3 shows a linear calibration curve of the 48–62 and 31–47 standard synthetic peptides. By determining the area of each ion chromatogram for the naturally processed HEL peptides 48–62 and 31–47 (Fig. 2B), the concentration of the recovered peptide was interpolated from the calibration curve. In the same experiment, the quantity of 48–62 peptide was 22.1 pmol compared with 1.01 pmol for the 31–47 peptide, indicating that the display of the 31–47 peptide was at least 22-fold lower than that of the 48–62.

**FIGURE 2.** Identification of the minor HEL peptides by electrospray mass spectrometry. The A6A2- and 3A9-positive fractions (shown in Fig. 1A) were dried down and reconstituted in 100 μl of 5% acetonitrile, 0.5% TFA. Fifteen percent of this sample was injected into the electrospray mass spectrometer, and after a 10-min delay, mass spectra were recorded continuously. A, [M + 2H]+ ions with an m/z of 863.3 and 913.9 correspond to the HEL peptides 48–62 (m/z 863.4) and 47–62 (m/z 914.0) (top). The three observed ions, 907.9+–, 957.7+–, and 1043.3+– represent the minor HEL peptides 31–46 (m/z 907.5), 31–47 (m/z 958.0), and 31–49 (m/z 1044.0) (bottom). B, Peptides eluted from the online HPLC are shown as the total ion chromatogram (TIC; top). The naturally processed HEL peptides, 31–47 and 48–62, eluted at 17 and 25 min, respectively. Reconstructed ion chromatograms were derived for these two peptides at an m/z range of 862.0–865.0 (middle) and 956.6–960 (bottom). The area under the 48–62 chromatogram was calculated at 327 × 10^6, and the area under the 31–47 chromatogram was 17.4 × 10^6. A broad ion chromatogram was observed for the 48–62 peptide due to overloading of the sample on the capillary reverse-phase HPLC column. (This could not be avoided because of the relatively low abundance of the 31–47 peptide.) The recovery for each peptide was derived from the calibration curve in Fig. 3.

**FIGURE 3.** Quantitation of the naturally processed HEL peptides 48–62 and 31–47. A linear calibration curve was acquired by injecting 15 μl of known concentrations (5, 10, 50, 100, and 500 fmol/μl) of synthetic 48–62 and 31–47 peptide into the electrospray mass spectrometer (□). The area of the ion chromatogram was determined and plotted against each peptide concentration. Using the same conditions, we injected 15 μl of the 100-μl peptide sample and obtained ion chromatograms for the naturally processed 48–62 and 31–47 peptides (shown in Fig. 2B). The peptide concentration of 48–62 (168 fmol/μl) and 31–47 (8 fmol/μl), shown in dark symbols, was interpolated from the respective calibration curves. The total amount of peptide 48–62 was 20.1 pmol compared with 1.01 pmol for the 31–47 peptide.
FIGURE 4. Identification of a minor HEL epitope by peptide-specific immunoaffinity. Class II I-A<sup>k</sup> molecules were purified from 10<sup>9</sup> B lymphoma cells. The associated peptides were released with 0.1% TFA, and HEL peptides containing the epitope FESNF were concentrated with the mAb VAL-3. The HEL peptides were injected into the reverse-phase HPLC online to the electrospray mass spectrometer, and mass spectra were acquired after 10 min. A. The m/z range of 600-1300 revealed no detectable HEL peptides from M12-A<sup>k</sup> cells. B. In M12-A<sup>k</sup> mHEL, doubly charged [M + 2H]<sup>2+</sup> ions ranging from 779<sup>2+</sup> to 1043.8<sup>2+</sup> were detected. Thirteen of these ions corresponded to HEL peptides (Table I), of which the two most abundant ions, 907<sup>2+</sup> and 957<sup>2+</sup>, corresponded to 31-46 and 31-47, respectively. Total ion chromatograms (TIC) are shown for the peptides eluted from M12-A<sup>k</sup> (C) and M12-A<sup>k</sup> mHEL (D) (note scale change). HEL peptides are eluted at 17.7, 18.0, and 18.2 min. Reconstructed chromatograms for the [M + 2H]<sup>2+</sup> ions 850.1<sup>2+</sup>, 907.2<sup>2+</sup>, 957.7<sup>2+</sup>, 1015.1<sup>2+</sup>, and 1043.8<sup>2+</sup> correspond to the 31 series of HEL peptides.
Isolation of the 31–47 HEL determinant by peptide-specific immunoaffinity

To improve the analysis of the 31–47 HEL epitopes, we developed an approach involving peptide-specific immunoaffinity chromatography. Class II I-A<sup>k</sup> molecules were purified from the lysates of M12-A<sup>k</sup> mHEL cells and from control M12-A<sup>k</sup> cells. The peptides associated with I-A<sup>k</sup> molecules were released by acid treatment, and HEL peptides were isolated by immunoaffinity capture using the Ab VAL-3 directed to the 34–45 peptide. These fractions were pooled and injected into the reverse-phase HPLC online to the electrospray mass spectrometer. Analysis of the total ion chromatogram from M12-A<sup>k</sup> mHEL shows no corresponding peptide (an example is provided in Fig. 4D). The total ion chromatogram was reconstructed for each HEL peptide (an example is provided in Fig. 4D). By contrast, the total ion chromatograms of M12-A<sup>k</sup> showed no corresponding HEL peptides (Fig. 4C).

Quantitation of HEL peptides extracted from I-A<sup>k</sup> molecules

We determined the recovery of peptides during the early steps of isolation and then attempted to quantitate them. First, the 125<sup>I</sup>-labeled HEL peptide 31–47 was incubated with purified class II I-A<sup>k</sup> for 48 h at room temperature. The 125<sup>I</sup>-labeled 31–47 complex was separated from free peptide and added to the cell lysate. The relative amount of peptide recovered after each step is shown in Table II. Thus, we estimated the peptide recovery to be about 50%.

Second, we were concerned that the more weakly binding 31–47 peptide might endure a preferential greater loss during the purification of I-A<sup>k</sup>. We addressed this issue by contrasting the recovery of 125<sup>I</sup>-labeled 31–47 peptide to the more strongly binding 125<sup>I</sup>-labeled 48–61 peptide. The peptides were incubated with purified class II I-A<sup>k</sup> molecules for 48 h, and then the complexes were isolated from free peptide by centrifugation through a BioSpin P6 gel filtration column. The complexes were added into the cell lysate and recovered from an anti-class II immunoaffinity chromatography column. In accordance with the results described above, the eluted material consisted of 42% 125<sup>I</sup>-labeled 31–47 peptide compared with 31% 125<sup>I</sup>-labeled 48–61. Thus, during the isolation of I-A<sup>k</sup>, there were no preferential losses of the 31–47 more weakly binding peptides.

We also examined the efficiency of our VAL-3 immunoaffinity column. Ten picomoles of synthetic 31–47 peptide in pH-neutralized 0.1% TFA solution was incubated with 500 μl of a 50% VAL-3-cyanogen bromide-activated Sepharose slurry (250-μl bed volume). The peptide was eluted, and the analysis was performed by MALDI-TOF mass spectrometry. A recovery of 77% was quantitated by comparing the abundance of the 31–47 peptide with our reference peptide (AAKFDSNFNTQASNRNT), which was added at 0.25 pmol/μl. Overall, the peptide recovery by the anti-peptide purification strategy before the mass spectrometry analysis was estimated to be 35%.

Finally, the naturally processed HEL peptides were recovered by peptide-specific immunoaffinity and quantitated by electrospray mass spectrometry. A calibration curve was generated for four sequence-specific synthetic peptides (residues 31–47, 32–47, 33–47, and 34–46) by injecting known amounts into the reverse-phase HPLC online to the electrospray mass spectrometer (Fig. 6). Using the same conditions as those for the standard peptides, we obtained ion chromatograms for each naturally processed HEL peptide (an example is provided in Fig. 4D) and calculated the area under each

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Observed [M + 2H]&lt;sup&gt;2+&lt;/sup&gt; Ions</th>
<th>Calculated&lt;sup&gt;‡&lt;/sup&gt; Mass [M&lt;sup&gt;+&lt;/sup&gt;]</th>
<th>Theoretical Mass [M&lt;sup&gt;+&lt;/sup&gt;]</th>
<th>Fragment</th>
<th>Sequence</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>850.1</td>
<td>1698.2</td>
<td>1698.8</td>
<td>31–45</td>
<td>AAKFESNFNTQATNR</td>
<td>15</td>
</tr>
<tr>
<td>2</td>
<td>907.2</td>
<td>1812.4</td>
<td>1812.9</td>
<td>31–46</td>
<td>AAKFESNFNTQATNRN</td>
<td>16</td>
</tr>
<tr>
<td>3</td>
<td>957.7</td>
<td>1913.4</td>
<td>1913.9</td>
<td>31–47</td>
<td>AAKFESNFNTQATNRNT</td>
<td>17</td>
</tr>
<tr>
<td>4</td>
<td>1015.1</td>
<td>2028.2</td>
<td>2028.9</td>
<td>31–48</td>
<td>AAKFESNFNTQATNRNTD</td>
<td>18</td>
</tr>
<tr>
<td>5</td>
<td>1043.8</td>
<td>2085.6</td>
<td>2086.0</td>
<td>31–49</td>
<td>AAKFESNFNTQATNRNTDG</td>
<td>19</td>
</tr>
<tr>
<td>6</td>
<td>814.3</td>
<td>1626.6</td>
<td>1627.8</td>
<td>32–45</td>
<td>AKFESNFNTQATNR</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>871.9</td>
<td>1741.8</td>
<td>1741.8</td>
<td>32–46</td>
<td>AKFESNFNTQATNRN</td>
<td>15</td>
</tr>
<tr>
<td>8</td>
<td>922.1</td>
<td>1842.2</td>
<td>1842.9</td>
<td>32–47</td>
<td>AKFESNFNTQATNRNT</td>
<td>16</td>
</tr>
<tr>
<td>9</td>
<td>1008.1</td>
<td>2014.2</td>
<td>2014.9</td>
<td>32–49</td>
<td>AKFESNFNTQATNRNTD</td>
<td>18</td>
</tr>
<tr>
<td>10</td>
<td>779.0</td>
<td>1556.0</td>
<td>1556.8</td>
<td>33–45</td>
<td>KFESNFNTQATNR</td>
<td>13</td>
</tr>
<tr>
<td>11</td>
<td>836.1</td>
<td>1670.2</td>
<td>1670.8</td>
<td>33–46</td>
<td>KFESNFNTQATNRN</td>
<td>14</td>
</tr>
<tr>
<td>12</td>
<td>886.9</td>
<td>1771.8</td>
<td>1771.8</td>
<td>33–47</td>
<td>KFESNFNTQATNRNT</td>
<td>15</td>
</tr>
<tr>
<td>13</td>
<td>972.6</td>
<td>1943.2</td>
<td>1943.9</td>
<td>33–49</td>
<td>KFESNFNTQATNRNTDG</td>
<td>17</td>
</tr>
</tbody>
</table>

<sup>‡</sup> Calculated mass = [(M + 2H)<sup>2+</sup> x 2) – 2.

Table I. Recovery of naturally processed peptides from membrane HEL B-lymphoma line
FIGURE 5. Sequence analysis of the naturally processed HEL peptides. Collision-activated dissociation was performed on the [M + 2H]^{2+} ions at an m/z of 907.2^{2+} (residues 31–46) (A) and 957.7^{2+} (residues 31–47) (B) using the Finnigan LCQ ion trap mass spectrometer. The sequence was acquired by comparing the observed masses of the y and b ions with those of the corresponding theoretical ions. Note that the following ions are not shown to scale: $b_{16}^{2+}$ (A) and 958.4^{2+} and $b_{17}^{2+}$ (B).
immunodominant HEL 48–61 peptide had an RIC volume of 80.

Isolated from the mAb VAL-3 were dried down and reconstituted in a total 47, and 33–47 were derived as described in Fig. 3. The HEL peptides squares Calibration curves (squares) for the synthetic peptides 31–46, 31–47, 32–47, and 33–47 were derived as described in Fig. 3. The HEL peptides isolated from the mAb VAL-3 were dried down and reconstituted in a total volume of 80 μl of 2% acetonitrile, 0.6% acetic acid. Using the same conditions for generating the calibration curve, we injected 19% (15 μl) of this sample into the electrospray mass spectrometer and obtained ion chromatograms for the 13 HEL epitopes shown in Fig. 4B, an example of which is shown in Fig. 4D. The amounts of four naturally processed peptides (shaded symbols) were interpolated from sequence-specific calibration curves, while the remaining peptides were interpolated from the calibration curve of the synthetic peptide most closely resembling the naturally processed one.

The most abundant HEL peptides, 31–47 and 31–46, were recovered at 1.3 pmol and 1 pmol, respectively (Table III). By comparison, the HEL peptide, 32–45 (4 fmol) had a 300-fold lower abundance. Interestingly, in every case the most abundant were the peptides ending at position 46 with asparagine, or at position 47 with threonine. The overall peptide recovery was 4 pmol from 109 cells.

Characterization of the subdominant HEL peptide 31–47 to I-Ak

Our current binding studies were performed using the most abundant HEL determinant, 31–47, instead of 34–45, which was studied previously (29). Binding strength assays against the reference peptide (RIC1 (1)) revealed the HEL 31–47 peptide to be a 30-fold weaker binder (RIC–1 (30)) (Fig. 7A). By comparison, the immunodominant HEL 48–61 peptide had an RIC–1 of 1.8, primarily attributed to the Asp12 anchoring residue (35, 38). SDS stability is a measure of the ability of a peptide to bind strongly to the class II αβ dimer. While the immunodominant HEL peptide 48–61 was 97% SDS stable, the minor 31–47 peptide ran virtually 100% SDS unstable (Fig. 7B).

Discussion

We isolated a family of peptides from HEL, of which the most abundant (residues 31–47) is about 22-fold less abundant than the dominant 48–62 peptides. These peptides also have considerably less binding strength for the I-Ak. The analysis of the 31–47 peptides indicates the many problems with the isolation and quantification of class II MHC bound peptides, which can be resolved by the method of peptide immunoaffinity isolation. In brief, the problems with peptide isolation from class II molecules stem from the fact that a wide range of peptides with varying degrees of affinities, lengths, and compositions binds to them. This is in contrast to those that bind class I, in which there appears to be a more restricted set of peptides with regard to all of these parameters. Class I bound peptides tend to consist of 8–10 residues and to be of high affinity and with strict restrictions in their use of anchoring residues. The assays for class II peptide analysis that are now in place, which combine T cell responses and chemical analysis, by necessity introduce a strong bias against low affinity binding peptides. These peptides in complex mixtures are required to be at a higher molar concentration (for the T cell assay) and could be competed

![Synthetic HEL peptides](image)

**FIGURE 6.** Quantitation of the minor HEL peptides presented by I-Ak. Calibration curves (squares) for the synthetic peptides 31–46, 31–47, 32–47, and 33–47 were derived as described in Fig. 3. The HEL peptides isolated from the mAb VAL-3 were dried down and reconstituted in a total volume of 80 μl of 2% acetonitrile, 0.6% acetic acid. Using the same conditions for generating the calibration curve, we injected 19% (15 μl) of this sample into the electrospray mass spectrometer and obtained ion chromatograms for the 13 HEL epitopes shown in Fig. 4B, an example of which is shown in Fig. 4D. The amounts of four naturally processed peptides (shaded symbols) were interpolated from sequence-specific calibration curves, while the remaining peptides were interpolated from the calibration curve of the synthetic peptide most closely resembling the naturally processed ones.

### Table II. Peptide recovery from peptide isolation protocola

<table>
<thead>
<tr>
<th>Step</th>
<th>Isolation Step</th>
<th>cpm</th>
<th>% Peptide Recovered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start</td>
<td>125I-31-47-Ak complex</td>
<td>1,024,600</td>
<td>100</td>
</tr>
<tr>
<td>1</td>
<td>Peptide-Ak bound to anti-class II column</td>
<td>922,007</td>
<td>90</td>
</tr>
<tr>
<td>2</td>
<td>Eluted peptide-Ak complex</td>
<td>539,055</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>Centricon-10-filtered free peptide</td>
<td>471,264</td>
<td>46</td>
</tr>
</tbody>
</table>

---

a 125I-31-47 peptide was incubated with 50 pmol of purified I-Ak. The complex was separated by centrifugation through a Bio-spin P6 gel filtration column after 48 h. The I-Ak purification protocol was followed. The peptide-Ak complex was spiked into 6 ml of cell lysate from the M12-AkB lymphoma line. At each step, samples were counted using the gamma counter to determine the percentage of peptide recovered.

### Table III. Total recovery of naturally processed HEL peptidesa

<table>
<thead>
<tr>
<th>Peptide Fragment</th>
<th>Peptide Recovery (fmol)</th>
<th>Total Estimated Content</th>
<th>Relative Yield (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>31–45†</td>
<td>40</td>
<td>114</td>
<td>0.96</td>
</tr>
<tr>
<td>31–46†</td>
<td>947</td>
<td>2,705</td>
<td>22.7</td>
</tr>
<tr>
<td>31–47***</td>
<td>1,273</td>
<td>3,637</td>
<td>30.5</td>
</tr>
<tr>
<td>31–48**</td>
<td>74</td>
<td>211</td>
<td>1.8</td>
</tr>
<tr>
<td>31–49***</td>
<td>261</td>
<td>746</td>
<td>6.3</td>
</tr>
<tr>
<td>32–45†</td>
<td>4</td>
<td>11</td>
<td>0.1</td>
</tr>
<tr>
<td>32–46†</td>
<td>222</td>
<td>634</td>
<td>5.3</td>
</tr>
<tr>
<td>32–47†</td>
<td>200</td>
<td>571</td>
<td>4.8</td>
</tr>
<tr>
<td>32–49†</td>
<td>47</td>
<td>134</td>
<td>1.1</td>
</tr>
<tr>
<td>33–45*</td>
<td>126</td>
<td>360</td>
<td>3.0</td>
</tr>
<tr>
<td>33–46*</td>
<td>418</td>
<td>1,194</td>
<td>10.0</td>
</tr>
<tr>
<td>33–47*</td>
<td>382</td>
<td>1,091</td>
<td>9.2</td>
</tr>
<tr>
<td>33–49*</td>
<td>177</td>
<td>506</td>
<td>4.2</td>
</tr>
<tr>
<td>Total</td>
<td>4,171</td>
<td>11,917</td>
<td>100</td>
</tr>
</tbody>
</table>

---

a Peptides were quantitated by mass spectrometry as described in Results. The amount of each naturally processed peptide was interpolated from four standard synthetic peptides, 31–46, 31–47, 32–47, 33–47. The recovery of each peptide was estimated to be 35%. The amount of class II I-Ak purified was determined by the Folin-Ciocalteu protein assay to be 2.4 × 106 molecules per APC, in accordance with recent direct estimates on cells (41). From this estimate and knowing the content of 11.9 pmol/106 cells, we concluded that 0.3% of the I-Ak molecules were occupied by the 31–47 series peptides. The purity of I-Ak was estimated to be 90% when resolved on a 12% SDS-polyacrylamide gel.
by other peptides in the mixture. Added to these issues are the loss of peptides during all the steps from class II isolation to the mass spectrometry analysis.

We can state with confidence that the 31–47 peptide family consists of truly minor peptides. The possibility that the peptides were displayed in large amounts but lost, or were not detected by T cell assay, has now been eliminated. There is considerable loss of peptides, as others have noted (39, 40), when we involve a first step of HPLC separation offline from the mass spectrometer (Figs. 1 and 2). For example, the recovery of 31–47 was 1.01 pmol per 10^10 cells (Fig. 2B) compared with the immunoaffinity capture procedure that yielded 12 pmol (in Fig. 6, we estimated a recovery of 1.2 pmol/10^6 cells) (i.e., about 92% of this peptide was lost during the initial analysis). Our estimates of occupancy of M12 C3.F6 (an APC very rich in I-A^k, about 1–2 × 10^6 sites per cell) with the 31–47 series peptide was about 0.3%. In our previous studies we estimated an occupancy with the 48–62 series of 6–9% (41). In summary, the immunoaffinity step bypasses the T cell assay, serves to concentrate the peptides, and permits a more reliable analysis and quantitation. We believe the use of a peptide immunoaffinity procedure will make it considerably easier to identify the whole spectrum of MHC-selected peptides from a known protein.

One factor that may determine the low representation of 31–47 peptides may be their affinity for I-A^k. In our analysis of HEL peptides, the most frequently displayed peptides bound to either I-A^k or I-E^k are those with high binding strength (9). Also, in the analysis of self-peptides bound to I-A^k, none is represented to the extent of 48–62, but neither do any of them display the high binding strength of 48–62. Nevertheless, more extensive analysis should tell us how strict the relationship is between extent of peptide display and binding strength for class II molecules. Concerning the 31–47 peptide, in ongoing studies we have been able to identify a major anchoring residue, Asn^39, as well as residues that hinder the binding. Whether Asn^39 fits into the P1 pocket of I-A^k (38) is not clear at present. Structural analysis of this peptide-I-A^k complex is in progress.

The family of 31–47 peptides, like many class II peptides, was displayed as a series varying in amino and carboxy termini. Here, the predominant species (about 53%) started at residue 31, ending at either 46 or 47. Our interpretation of the reasons for these nested peptides lies in the nature of the processing event. Our data lead us to believe that HEL is first denatured, allowing the opened molecule to interact with I-A^k molecules. I-A^k molecules select the segments of HEL bearing the higher affinity sequences. Once bound, the segment is protected from catabolism but is then trimmed by amino- and carboxypeptidases. Trimming extends to the edges of the combining site but is somewhat variable, leaving ends of different size. Our data are supported by experiments in which the addition of proline to the flanking residues of HEL-dominant peptide resulted in extensions of the peptide (11). We favor this scenario over other possibilities, such as an initial cutting of the molecule by cathepsins with subsequent selection of peptides. With this in mind, it is likely that presentation of the dominant segment, 48–62, may hinder the presentation of the 31–47 segment. We can conclude that at least 13% of the HEL molecules that donate the 31–47 epitope cannot donate the 48–62 epitope (i.e., the 13% that end up in residue 49). Future studies in which the main anchor residue of the 48–62 segment is mutated may give us information on the relationship between these two segments in binding I-A^k in vivo.

Acknowledgments

We thank Ms. Shirley Petzold for technical assistance, Ms. Mary Walton for proofreading the manuscript, and Ms. Janet Casmaer for preparation of the manuscript.

References


